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Radiation myelitis after hypofractionated
radiotherapy with concomitant gefitinib
Victor Lewitzki1,4*, Nicolaus Andratschke1,2, Thomas Kuhnt1,3 and Guido Hildebrandt1
Abstract
We describe the case of a 71-year-old Caucasian female with primary disseminated non-small cell cancer of the
lung, presented for palliative radiotherapy of metastatic spread to the 9th and 11th thoracic vertebrae without
intramedullary growth. Palliative radiotherapy with daily fractions of 3 Gy and a cumulative dose of 36 Gy to thoracic
vertebrae 8-12 was performed. The patient received concomitantly 250 mg gefitinib daily. After a latent period of 16
months, the patient developed symptoms of myelitis. Magnetic resonance imaging (MRI) did not reveal any bony or
intraspinal tumor progression, but spinal cord signal alteration. No response to steroids was achieved. The neurological
symptoms were progressive in August 2013 with the right leg being completely plegic. The left leg was incompletely
paralyzed. Deep and superficial sensitivity was also diminished bilaterally. The patient was completely urinary and anally
incontinent. Contrary to the clinical findings, a follow-up MRI (July 2013) showed amelioration of the former signal
alterations in the spinal cord. The diagnosis of paraneoplastic myelopathy was refuted by a negative test for autologous
antibodies. At the last clinical visit in May 2014, the neurological symptoms were stable. The last tumor-specific treatment
the patient is receiving is erlotinib 125 mg/d.
We reviewed the literature and found no reported cases of radiation myelopathy after the treatment in such a setting.
The calculated probability of such complication after radiotherapy alone is statistically measurable at the level of 0.02%.
We suppose that gefitinib could also play a role in the development of this rare complication.
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Background
Radiation myelitis [RM] is a rare condition, since modern
treatment techniques with a homogeneous dose distribu-
tion are available and critical doses for human spine are
well known. Thus a moderate hypofractionated radiother-
apy of the thoracic spine with 36 Gy in 12 daily fractions
of 3 Gy is believed to be safe. A possible interaction of
spinal cord irradiation with gefitinib is not known.
Radiobiological experiments indicate a possible inter-
action with gefitinib in some selected cancer cell lines.
No data on normal tissue tolerance of this combination
are available.
Lung cancer is a common malignant disease, often
with distant metastases as first presenting sign of malig-
nant disease. The common site of spread is the skeleton,
with symptomatic vertebral spread sometimes causing
the first symptoms of this disease. Along with palliative
chemotherapy and bone modifying agents, radiotherapy
plays an important role in the palliation of symptomatic
bone metastases. Due to progress in treatment planning
and delivery, allowing for a better dose distribution and
homogenous dose application, and growing experience
in the tolerance of human spinal cord to irradiation, ra-
diation myelitis is fortunately a rare but severe complica-
tion of irradiation.
A hypofractionated treatment schedule is a common
option for radiotherapy in a palliative setting. The main
goal of such a treatment is good symptom control with
short treatment time. A total dose of 36 Gy in 12 daily
fractions of 3 Gy is a possible fractionation schedule for
the treatment of bone metastases. One meta-analysis of
three randomized studies in patients with non-small cell
lung cancer (NSCLC) revealed no cases of radiation
myelitis in 86 patients treated by this modality [1].
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Gefitinib is a selective inhibitor of the tyrosine kinase. It
is approved for primary treatment of metastatic lung
adenocarcinoma with epidermal growth factor receptor
(EGFR) gene mutation. The low rate of adverse events
and often prolonged response make its use very attractive
especially in the palliative situation [2]. There are several
trials and retrospective series also demonstrating its activ-
ity in disease metastatic to the central nervous system.
Dose dependence in achieving objective and clinical re-
sponse was reported [3]. Findings from these studies are
at least suggestive of interactions between ionizing radi-
ation and gefitinib [4,5]. There are also radiobiological
studies to support an interaction of gefitinib in at least
some cell lines [6-8].
To date, we have found just one reported case of ra-
diation myelitis after concomitant definitive high-dose
radiation and chemotherapy including gefitinib [9].
In this article we present a case of radiation myelopathy
after palliative radiotherapy applying a dose of 36 Gy in 12
fractions to the 8-12 thoracic vertebrae concomitant with
250 mg/m2 gefitinib daily.
Case report
In June 2011, a 70-year-old female Caucasian patient pre-
sented with weight loss and hematuria in a local hospital.
Further diagnostics revealed lung tumor in the left lobe
with multiple pulmonary, liver, left adrenal gland and bone
metastases, including pathological fracture of the 11th ver-
tebra. The tumor cytology showed adenocarcinoma. Thus,
palliative chemotherapy with carboplatin/paclitaxel was
administered. A further genetic analysis of a tumor biopsy
proved EGFR mutation at exon 19. After another hospital
attendance due to urinary infection with complications,
the chemotherapy was stopped and targeted therapy with
gefitinib at a dose of 250 mg/m2 was started on August
27, 2011. In September 2011, a palliative course of radio-
therapy with daily single doses of 3 Gy to a total dose of
36 Gy was administered to vertebrae 8-12 for symptom-
atic metastatic spread to thoracic vertebrae 9 and 11 with-
out extraosseous and intraspinal tumor manifestations.
Daily concomitant administration of gefitinib was con-
tinued. On the last day of radiotherapy, the patient was
reported to be completely free of metastasis-related
symptoms.
In December 2011, restaging proved partial response
of primary tumor and lung metastases with complete re-
sponse of liver and adrenal metastases. Maintenance
therapy with gefitinib was continued. In March 2012,
the patient presented with back pain approximately at
level Th 6-7. Restaging with thoracic and abdominal
computed tomography in April 2012 showed stable dis-
ease as compared to December 2011. In August 2012,
the bisphosphonate therapy was stopped due to no
otherwise specified adverse events and was switched to
denosumab. Due to progressive disease revealed in
September 2012, systemic therapy was changed to
pemetrexed and continued after achieving stable dis-
ease in December 2012.
16 months after radiotherapy (January 2013), the pa-
tient presented with pain in her right hip radiating down
to the lower leg. Spinal computed tomography in February
2013 did not reveal any progression of bony spinal me-
tastases. The patient did not respond to analgesic ther-
apy with Tapentadol 3×100 mg/die. Due to neuropathic
complaints in the right leg and muscular weakness, the
patient was hospitalized to the Neurological department
of the regional clinic in February 2013. Spinal MRI with
gadolinium contrast agent showed T2-hypertintense
spinal cord lesions in segment Th 7-10 with a little con-
trast enhancement on T1 and isointense in native T1
(Figure 1a, b). Cranial MRI revealed one small cerebellar
lesion suspected to be of metastatic origin. Spinal fluid
taken was negative for tumor cells. On neurological
examination, pyramid signs were negative. The muscle
tonus, and the deep and superficial sensitivity of the
right leg were diminished. Electromyography of right m.
tibialis anterior and m. rectus femoris showed no patho-
logical spontaneous activity. Controlled muscular activ-
ity was sluggish.
The patient was consulted in our Radiological depart-
ment. We consulted with our Radiologist on the MRIs and
discussed differential diagnoses. A diagnosis of radiation-
induced myelopathy was suspected and dexamethasone
was proposed as a therapy for myelitis. The patient did not
respond to intravenous dexamethasone 24 mg/die. A few
weeks later, she became urinary incontinent. Some pain
relief could be obtained with pregabalin 75 mg bid. The
patient continued her palliative chemotherapy in an out-
patient setting.
The neurological symptoms were progressive in August
2013 with the right leg being completely plegic. The left
leg was incompletely paralyzed. Deep sensitivity was
completely absent in the whole right leg and up to the
knee on the left side. Superficial sensitivity was also di-
minished in accordance with deep sensitivity bilaterally.
The patient was completely urinary and anally incontin-
ent. Contrary to the clinical findings, a follow-up MRI
(July 2013) showed amelioration of the former signal
alterations in the spinal cord (Figure 1c, d). The diag-
nosis of paraneoplastic myelopathy was refuted by a
negative test for autologous antibodies performed in
our institution.
At the last visit (May 2014), the neurological symp-
toms were stable in comparison with the state in August
2013. At the last restaging (April 2014) of the thoracic
CT, the primary tumor was slightly progredient. No
intraspinal changes were described in the thoracic CT.
The current targeted therapy contains erlotinib in the
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highest tolerable dosage for this patient of 125 mg daily.
Before the last progression, the patient received erlotinib
100 mg daily with diarrhea being a dose-limiting toxicity.
Discussion
In recent decades, radiation myelitis has become a rare
complication, reflecting the confidence and expertise in
dose prescription and delivery due to sophisticated tech-
niques and clinical expertise of spinal cord tolerance. In
the current literature, one can find more discussion on
the problems of radiosurgery with high single dose irradi-
ation or re-irradiation of spinal cord or adherent struc-
tures, rather than clinical findings of radiation myelitis
following conventional radiotherapy [10]. On the other
hand, the rapid progress in drug development, with a
plethora of novel targeted drugs and a lack of basic radio-
biological data on their combination with radiotherapy,
has left us with questions about possible interactions each
time, when such toxicity follows our well known “thought
to be safe” therapeutic regimen. Nevertheless, long-lasting
responses with these new substances can be achieved in
some patients, thus giving our patients the chance of
longer survival and the development of complications
rarely before seen due to previously limited survival rates.
The diagnosis in our case was supported by the typical
clinical picture with symptom onset at 16 months after
radiotherapy with progressive sensory and motor loss,
urinary incontinence and typical MRI presentation, con-
sistent with well-known data [11,12], with a posteriorly
located ring-shaped contrast-enhanced lesion at the ir-
radiated level and extensive edema in the upper part
outside the treatment field. Neurological findings were
also consistent with RM diagnosis. The progressive clin-
ical neurological deficits with the corresponding radio-
logical findings without evidence of progressive metastatic
lesions are typical of the development of RM refuting
intraspinal metastasis. Finally, in the absence of auto-
antibodies (aminophysin, CV2, PNMa2, Ri, Anti-Yo, Hu)
the diagnosis of paraneoplastic myelopathy could be with-
drawn. Thus, not having a histological confirmation, we are
confident of the diagnosis of RM in the case described. The
treatment with steroids, having a limited influence on the
development of this complication, cannot assist in proving
or withdrawing the diagnosis of RM.
Figure 1 Thoracic cord magnetic resonance imaging of 71 year old patient in the course of radiation myelitis. a) February 2013:
T1-weighted MRI scan without contrast shows hyperintense post-actinic changes in vertebrae Th 8-12, isointense changes in segments Th 7-9
and Th 11 fracture. b) February 2013: T1-weighted MRI with gadolinium demonstrates a ring-shaped posterior enhancement in spinal cord (arrow)
at the level of Th 8-9. c) July 2013: T1-weighted MRI with gadolinium demonstrates a decrease of the ring-shaped posterior enhancement in
spinal cord (arrow) at the level of Th 8-9 in comparison with the previous study (Figure 1b). d) July 2013: T2-weighted MRI scans demonstrate no
signs of edema.
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Using the linear-quadratic model generally adopted
to compare a dose normalized to conventional frac-
tionation (EQD2) (EQD2 ¼ D 
dþ αβð Þ
2Gyþ αβð Þ with α/β = 3
Gy, D = cumulative dose and d = dose per fraction), the
doses applied to the patient equal an EQD2 of 43.2 Gy.
Even after applying an α/β of 2 Gy an EQD2 of 45 Gy is
still considered to be safe. Using the data of Schultheiss
[13], evaluating the radiation dose response for cervical
spinal cord to be more sensitive than thoracic [14], we
can assume that a probability of myelopathy at EQD2
45 Gy is lower than 0.03 percent.
Using data of the QUANTEC review [15], we could
suggest a probability of 0.2 percent of myelopathy after
conventional fractionated radiation with 50 Gy in 2 Gy
single fractions, but not after the hypofractionated radiation
being applied in this case.
Dunst et al. reported one case of radiation myelitis
after application of a total of 25 Gy in 5 daily fractions
of 5 Gy, assuming a maximal dose at spinal cord of 27
Gy, (EQD2 49.95 Gy with α/β =2) [16]. Also looking at
this case of above-average radiation sensitivity, it should
be mentioned that EQD2 in the case reported by Dunst
et al. is 4.95 Gy higher than in our patient.
Macbeth et al. reported 5 cases of radiation myelop-
athy among 1048 patients with inoperable non-small cell
lung cancer, treated with palliative radiotherapy in three
randomized trials conducted by the Medical Research
Council Lung Cancer Working Party. Of the 5 instances
of radiation myelopathy, 3 occurred in the 524 patients
treated with 17 Gy in 2 fractions, and 2 in the 153 pa-
tients treated with 39 Gy in 13 fractions. There was also
a group of 86 patients treated with 36 Gy in 12 fractions.
The annual risks in this study had wide 95% confidence
intervals. According to this study, the authors are sug-
gesting that α/β is possibly close to 2 Gy [1].
Matha et al. described a case of a 47-year-old male
who developed a cervical myelopathy after radiochemo-
therapy of tongue cancer. For this patient a total dose of
70 Gy over 7 weeks concurrently with weekly cisplatin
of 40 mg/m2 was applied. The maximum dose in the
spinal cord was limited to 44.8 Gy. The first symptom,
developing in this patient approximately 7 months after
radiotherapy, was sensory loss bilaterally from the nipples
down. His symptoms worsened and he also developed
bowel and bladder incontinence, gait instability and mild
weakness of all four extremities. He had diminished sensa-
tion to light touch, pinprick, and temperature from C4
down. Magnetic resonance imaging of his spinal cord
revealed a bright lesion at T2, accumulating gadolinium
with corresponding enhancement at T1 [17]. This patient
died consequently on the sequela of RM.
Considering possible limitations of radiobiological models,
we want to emphasize that empiric data from previous
studies, reporting no cases of radiation myelitis with
this fractionation schedule, do not exclude the possi-
bility of radiation myelitis after a cumulative dose of 36
Gy in 12 daily fractions. There are also some limita-
tions using older data from 2-D planned radiotherapy,
due to relatively imprecise dosimetry and inhomogeneous
dose distribution with hot spots regularly presented inside
target volumes.
Discussing the possible influence of gefitinib on the ra-
diosensitivity of spinal cord, one should consider that
experimental data addressing this question do not exist.
There are two widely accepted means of organ damage
in the pathogenesis of RM: damage of glial cells (glial
theory) and damage of vascular endothelial cells (vascu-
lar hypothesis). The latter seems to be better proven by
experimental data and observations, in that the vascular
architecture of the spinal cord can often be aligned with
pathological patterns of myelitis [18]. There are also ex-
perimental [19,20] and clinical data [21,22] published,
indirectly supporting the vascular hypothesis. Gefitinib
seems to suppress mobilization of pericytes needed for
vessel stabilization [20], at least in tumor models.
There are clinical data from phase I and III studies,
showing a higher occurrence of tumor hemorrhage
under treatment with gefitinib concurrent to IR [22,9].
One out of 23 patients treated with radiation and con-
current carboplatin, paclitaxel and gefitinib, developed
grade 3 anterior spinal cord syndrome. Spinal cord in-
farct within the radiation field was the probable reason.
The clinical changes started 8 months after completion
of radiation and 2 weeks after discontinuing gefitinib.
The symptoms were lower extremity weakness and tin-
gling for 1 to 2 months and new onset of urinary reten-
tion. The total maximal calculated dose in spinal cord
was 49.6 Gy. The patient was evaluated with magnetic
resonance imaging of the spine, which was negative for
cord compression. A lumbar puncture was negative for
malignant cells [9].
Experimental data, answering the same question in
normal tissues irradiated, especially in mammalian spinal
cord, are needed to answer this specific question.
Until these data are available, we suggest paying spe-
cial attention when using concurrent radiotherapy with
gefitinib, in particular with spinal cord being a part of
the target volume and if the cervical or thoracic spine is
involved.
Conclusion
Radiotherapy with a cumulative dose of 36 Gy in 12
daily fractions of 3 Gy is believed to be a safe option for
the palliative treatment of vertebral metastasis. Myelitis
is a rare complication at this dose level. There are no
data about this complication as a sequela of concomitant
radiotherapy to 36 Gy with gefitinib. Until more clinical
Lewitzki et al. Radiation Oncology  (2015) 10:29 Page 4 of 5
data are available, we suggest that a combination of radio-
therapy and gefitinib should be used with caution regard-
ing their possible interaction in tissue reactions of the
spinal cord.
We also suggest being especially cautious in choosing
the modality of palliative radiotherapy for patients with
NSCLC with known EGFR mutation. Due to the tar-
geted therapies, some of these patients can achieve very
long survival thus having time to develop late sequelae
of radiation therapy.
Consent
The patient has given her written consent for the case
report to be published.
Competing interests
On behalf of all authors, the corresponding author states that there is no
conflict of any financial or non-financial competing interest.
Authors’ contributions
VL performed clinical examinations of the patient and gathered related
information from medical facilities. VL and NA carried out the retrospective
analysis of the clinical case, participated in the conception and design and
drafted the manuscript. TK and GH participated in the conception and
design, reviewed the radiation treatment chart and the available related
literature. All authors read and approved the final manuscript.
Author details
1Department of Radiation Oncology, University Medicine Rostock, Südring
75, 18059 Rostock, Germany. 2Department of Radiation Oncology, University
Zürich, Rämistrasse 100, 8091 Zürich, Switzerland. 3Department of Radiation
Oncology, University Leipzig, Stephanstraße 9a, 04103 Leipzig, Germany.
4Department of Radiation Oncology, University Würzburg, Joseph Schneider
Str. 11, 97080 Würzburg, Germany.
Received: 23 June 2014 Accepted: 14 January 2015
References
1. Macbeth FR, Wheldon TE, Girling DJ, Stephens RJ, Machin D, Bleehen NM,
et al. Radiation myelopathy: estimates of risk in 1048 patients in three
randomized trials of palliative radiotherapy for non-small cell lung cancer:
the Medical Research Council Lung Cancer Working Party. Clin Oncol
(R Coll Radiol). 1996;8:176–81.
2. Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager D, Belani CP, et al. Efficacy of
gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine
kinase, in symptomatic patients with non-small cell lung cancer: a randomized
trial. JAMA. 2003;290:2149–58.
3. Jackman DM, Holmes AJ, Lindeman N, Wen PY, Kesari S, Borras AM, et al.
Response and resistance in a non-small-cell lung cancer patient with an
epidermal growth factor receptor mutation and leptomeningeal metastases
treated with high-dose gefitinib. J Clin Oncol. 2006;24:4517–20.
4. Tanaka T, Munshi A, Brooks C, Liu J, Hobbs ML, Meyn RE. Gefitinib
radiosensitizes non-small cell lung cancer cells by suppressing cellular DNA
repair capacity. Clin Cancer Res. 2008;14:1266–73.
5. Ready N, Jänne PA, Bogart J, Dipetrillo T, Garst J, Graziano S, et al.
Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with
epidermal growth factor receptor and KRAS mutation analysis: cancer and
leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial. J Thorac
Oncol. 2010;5:1382–90.
6. Kang KB, Zhu C, Wong YL, Gao Q, Ty A, Wong MC. Gefitinib radiosensitizes
stem-like glioma cells: inhibition of epidermal growth factor receptor-Akt-DNA-PK
signaling, accompanied by inhibition of DNA double-strand break repair. Int J
Radiat Oncol Biol Phys. 2012;83:e43–52.
7. Park S-Y, Kim YM, Pyo H. Gefitinib radiosensitizes non-small cell lung cancer
cells through inhibition of ataxia telangiectasia mutated. Mol Cancer.
2010;9:222.
8. Chen F-H, Fu S-Y, Yang Y-C, Wang C-C, Chiang C-S, Hong J-H. Combination
of vessel-targeting agents and fractionated radiation therapy: the role of the
SDF-1/CXCR4 pathway. Int J Radiat Oncol Biol Phys. 2013;86:777–84.
9. Stinchcombe TE, Morris DE, Lee CB, Moore DT, Hayes DN, Halle JS, et al.
Induction chemotherapy with carboplatin, irinotecan, and paclitaxel
followed by high dose three-dimension conformal thoracic radiotherapy
(74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable
stage IIIA and stage IIIB non-small cell lung cancer. J Thorac Oncol.
2008;3:250–7.
10. Supe SS, Ganesh KM, Naveen T, Jacob S, Sankar BN. Spinal cord response to
altered fractionation and re-irradiation: radiobiological considerations and
role of bioeffect models. J Cancer Res Ther. 2006;2:105–18.
11. Higashida T, Colen CB, Guthikonda M. Diagnostic and therapeutic strategy
for confounding radiation myelitis. Clin Neurol Neurosurg. 2010;112:353–6.
12. Koehler PJ, Verbiest H, Jager J, Vecht CJ. Delayed radiation myelopathy:
serial MR-imaging and pathology. Clin Neurol Neurosurg. 1996;98:197–201.
13. Schultheiss TE. The radiation dose-response of the human spinal cord. Int J
Radiat Oncol Biol Phys. 2008;71:1455–9.
14. Adamus-Gorka M, Brahme A, Mavroidis P, Lind BK. Variation in radiation
sensitivity and repair kinetics in different parts of the spinal cord. Acta
Oncol. 2008;47:928–36.
15. Marks LB, Yorke ED, Jackson A, Ten Haken RK, Constine LS, Eisbruch A, et al.
Use of normal tissue complication probability models in the clinic. Int J
Radiat Oncol Biol Phys. 2010;76:S10–9.
16. Dunst J, Gebhart E. Unexpected tumor response, radiation myelitis and increased
in vitro-radio-sensitivity of lymphocytes in a patient with non-small lung
cancer. Radiother Oncol. 1995;36:158.
17. Mahta A, Borys E, Kanakamedala MR, Kesari S. Radiation induced myelopathy in
a patient with tongue cancer: a case report. Acta Oncol. 2012;51:409–11.
18. Okada S, Okeda R. Pathology of radiation myelopathy. Neuropathology.
2001;21:247–65.
19. Ceresoli GL, Cappuzzo F, Gregorc V, Bartolini S, Crinò L, Villa E. Gefitinib in
patients with brain metastases from non-small-cell lung cancer: a prospective
trial. Ann Oncol. 2004;15:1042–7.
20. Iivanainen E, Lauttia S, Zhang N, Tvorogov D, Kulmala J, Grenman R, et al.
The EGFR inhibitor gefitinib suppresses recruitment of pericytes and bone
marrow-derived perivascular cells into tumor vessels. Microvasc Res.
2009;78:278–85.
21. Stewart JS, Cohen EE, Licitra L, Van Herpen CM, Khorprasert C, Soulieres D,
et al. Phase III study of gefitinib compared with intravenous methotrexate
for recurrent squamous cell carcinoma of the head and neck [corrected].
J Clin Oncol. 2009;27:1864–71.
22. Geyer JR, Stewart CF, Kocak M, Broniscer A, Phillips P, Douglas JG, et al. A
phase I and biology study of gefitinib and radiation in children with newly
diagnosed brain stem gliomas or supratentorial malignant gliomas. Eur J
Cancer. 2010;46:3287–93.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Lewitzki et al. Radiation Oncology  (2015) 10:29 Page 5 of 5
